Richard Lake
机构: Professor University of Western Australia
每年引用次数
引用次数
引用: 12,964
H-指数: 53
I10-指数 : 108
出版物: 209
A monoclonal DNA-binding autoantibody causes a deterioration in renal function in MRL mice with lupus disease.
R A Lake , N A Staines
Clinical and Experimental Immunology 73 ( 1) 103
13
1988
A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis.
B Henderson , R A Lake , N A Staines , A Morgan
Immunology 54 ( 2) 389 -395
32
1985
Polyclonal and clonal analysis of human CD4+ T-lymphocyte responses to nut extracts.
R E O'Hehir , J A Higgins , R A Lake , J R Lamb
Immunology 84 ( 1) 91 -97
49
1995
The effects of changes at peptide residues contacting MHC class II T-cell receptor on antigen recognition and human Th0 cell effector function.
J D Hayball , R E O'Hehir , C Hetzel , J A Higgins
Immunology 85 ( 3) 447 -454
15
1995
Harnessing the immune response to treat cancer.
H J Steer , R A Lake , A K Nowak , B W S Robinson
Oncogene 29 ( 48) 6301 -6313
69
2010
p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
J Creaney , B M McLaren , S Stevenson , A W Musk
British Journal of Cancer 84 ( 1) 52 -56
22
2001
Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all
R G van der Most , A J Currie , B W S Robinson , R A Lake
Cell Death & Differentiation 15 ( 1) 13 -20
54
2008
Oligoclonal V gene usage by T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients.
C M Jones , R A Lake , J B Wijeyekoon , D M Mitchell
American Journal of Respiratory Cell and Molecular Biology 14 ( 5) 470 -477
20
1996
Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.
M J McCoy , R A Lake , R G van der Most , I M Dick
British Journal of Cancer 107 ( 7) 1107 -1115
44
2012
Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer.
M J McCoy , C Hemmings , T J Miller , S J Austin
British Journal of Cancer 113 ( 12) 1677 -1686
38
2015
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
T M Meniawy , J Creaney , R A Lake , A K Nowak
British Journal of Cancer 109 ( 7) 1813 -1820
33
2013
Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma’
T M Meniawy , J Creaney , R A Lake , A K Nowak
British Journal of Cancer 111 ( 12) 2377 -2377
1
2014
Production of monoclonal antibodies
A. Morgan , N. Staines , R. Lake
Society of Applied Bacteriology. Technical series ( 24) 1 -19
5
1987
Routinely collected clinical and laboratory data can reliably predict longer survival in malignant pleural mesothelioma
T. Meniawy , A. Nowak , J. Creaney , Fraser Brims
Respirology 19 16 -16
2014
17 Gene expression profiling in an SV40 large T antigen expressing transgenic mouse mesothelioma model. Implications for a role for SV40 in human mesothelioma
C. Robinson , D. Diyagama , H. Pass , C. Webb
Lung Cancer 54
2006
Gene therapy or therapy with intratumoral cytokines by infusion in mesothelioma patients
A. Davidson , S. Morey , A.W. Musk , I. Ramshaw
Lung Cancer 18 94 -95
4
1997
926 Intralesional vaccinia virus-interleukin 2 (VV-IL2) gene therapy in malignant mesothelioma (MM)
S. Mukherjee , T. Haenel , M. Epton , R. Lake
Lung Cancer 18 236
5
1997
263 Up regulation of PD-L1 on peripheral blood CD3+ T cells predicts poor prognosis in patients with non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) inhibitors
T. Meniawy , R. Lake , A. McDonnell , M. Millward
European Journal of Cancer 51
1
2015
S59 Chemo-immunotherapy of mesothelioma: depletion of established, suppressive CD4 T cells is critical to achieving cures in a murine model
H. J. Steer , A. Cleaver , A. Nowak , B. Robinson
Thorax 66
1
2011
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used.
Vanessa S Fear , Catherine A Forbes , Samuel A Neeve , Scott A Fisher
Cancer Immunology, Immunotherapy 1 -10
2021